RxDoctor Payments Data

Sami Hayek, MD

Interventional Cardiology · Covina, CANPI 1992024483

Payments from drug & device makers

$53,873in general payments, 2019–2025

Across 544 payments — averaging $99.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$31K
  • Abiomed$10K
  • Boehringer Ingelheim International GmbH$2K
  • Abbott$2K
  • Medtronic$2K
  • Novartis$1K
  • plus $5K from 33 others
$219in research payments, 2019–2025

Across 2 payments — averaging $109.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abiomed$219

What the payments were for

  • Speaking & faculty fees$6,00030%
  • Travel & lodging$1,6568%
  • Food & beverage$12,63962%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$53,873 in reported general payments places this provider in the 75th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$355,316
Medicare patients
971
Services billed
2,946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$295,175
EntrestoSacubitril/Valsartan237$193,320
XareltoRivaroxaban48$45,907
BrilintaTicagrelor52$32,557
FarxigaDapagliflozin Propanediol27$31,874
Repatha SureclickEvolocumab37$29,668
Rosuvastatin Calcium308$5,276
Praluent PenAlirocumab11$5,266
Metoprolol Succinate265$3,668
Hydralazine Hcl274$2,847
Atorvastatin Calcium313$2,837
Ranolazine ErRanolazine22$2,738
Losartan Potassium259$2,264
Ezetimibe110$2,097
Amiodarone Hcl53$1,594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$908$295,175309 claims
NovartisEntresto$1,282$193,320237 claims
AstraZenecaBrilinta, Farxiga$269$64,43079 claims
Johnson & JohnsonXarelto$309$45,90748 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Covina

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →